QIAGEN Total Liabilities 2010-2022 | QGEN

QIAGEN total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • QIAGEN total liabilities for the quarter ending March 31, 2022 were $2.944B, a 1.07% increase year-over-year.
  • QIAGEN total liabilities for 2021 were $3.05B, a 0.7% decline from 2020.
  • QIAGEN total liabilities for 2020 were $3.072B, a 13.81% increase from 2019.
  • QIAGEN total liabilities for 2019 were $2.699B, a 13.31% decline from 2018.
QIAGEN Annual Total Liabilities
(Millions of US $)
2021 $3,050
2020 $3,072
2019 $2,699
2018 $3,113
2017 $2,498
2016 $1,701
2015 $1,611
2014 $1,796
2013 $1,365
2012 $1,363
2011 $1,172
2010 $1,438
2009 $1,505
QIAGEN Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $2,944
2021-12-31 $3,050
2021-09-30 $3,030
2021-06-30 $2,930
2021-03-31 $2,913
2020-12-31 $3,072
2020-09-30 $3,060
2020-06-30 $2,674
2020-03-31 $2,689
2019-12-31 $2,699
2019-09-30 $2,675
2019-06-30 $2,750
2019-03-31 $2,814
2018-12-31 $3,113
2018-09-30 $2,772
2018-06-30 $2,785
2018-03-31 $2,525
2017-12-31 $2,498
2017-09-30 $2,530
2017-06-30 $2,051
2017-03-31 $1,638
2016-12-31 $1,701
2016-09-30 $1,662
2016-06-30 $1,492
2016-03-31 $1,495
2015-12-31 $1,611
2015-09-30 $1,639
2015-06-30 $1,594
2015-03-31 $1,691
2014-12-31 $1,796
2014-09-30 $1,748
2014-06-30 $1,809
2014-03-31 $1,754
2013-12-31 $1,365
2013-09-30 $1,379
2013-06-30 $1,381
2013-03-31 $1,343
2012-12-31 $1,363
2012-09-30 $1,245
2012-06-30 $1,235
2012-03-31 $1,163
2011-12-31 $1,172
2011-09-30 $1,364
2011-06-30 $1,404
2011-03-31 $1,422
2010-12-31 $1,438
2010-09-30 $1,460
2010-06-30 $1,433
2010-03-31 $1,469
2009-12-31 $1,505
2009-09-30 $1,526
2009-06-30 $1,436
2009-03-31 $1,370
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.865B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00